3D model (JSmol)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Vitamin D5 is a form of vitamin D.
Analogues have been proposed for use as antitumor agents. Studies on vitamin D3 has shown inhibition of cell proliferation in prostate cancer, but vitamin D3 also results in hypercalcemia. Analogs of vitamin D5 have also been used to study its effects on prostate cancer, but unlike vitamin D3, vitamin D5 not only leads to inhibition of cell proliferation, but also does not cause hypercalcemia.
- Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, Guo L (February 1997). "Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5". Journal of the National Cancer Institute. 89 (3): 212–8. doi:10.1093/jnci/89.3.212. PMID 9017001.
- Murillo G, Mehta RG (October 2005). "Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5". The Journal of Steroid Biochemistry and Molecular Biology. 97 (1–2): 129–36. doi:10.1016/j.jsbmb.2005.06.008. PMID 16051482.
- Mehta RG (October 2004). "Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5". European Journal of Cancer. 40 (15): 2331–7. doi:10.1016/j.ejca.2004.05.025. PMID 15454260.
- Mooso B, Madhav A, Johnson S, Roy M, Moore ME, Moy C, Loredo GA, Mehta RG, Vaughan AT, Ghosh PM (November 2010). "Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog". Genes & Cancer. 1 (9): 927–940. doi:10.1177/1947601910385450. PMC 3089062. PMID 21552398.
|This biochemistry article is a stub. You can help Wikipedia by expanding it.|